Budesonide
- Generic Name
- Budesonide
- Brand Names
- Airsupra, Breyna, Breztri, Cortiment, Entocort, Pulmicort, Pulmicort Turbuhaler, Rhinocort, Symbicort, Tarpeyo, Uceris, Jorveza, Kinpeygo
- Drug Type
- Small Molecule
- Chemical Formula
- C25H34O6
- CAS Number
- 51333-22-3
- Unique Ingredient Identifier
- Q3OKS62Q6X
- Background
Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.
Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product with formoterol.
- Indication
Budesonide extended release capsules are indicated for the treatment and maintenance of mild to moderate Crohn’s disease. Various inhaled budesonide products are indicated for prophylactic therapy in asthma and to reduce exacerbations of COPD. A budesonide nasal spray is available over the counter for symptoms of hay fever and upper respiratory allergies. Extended-release capsules are indicated to induce remission of mild to moderate ulcerative colitis and a rectal foam is used for mild to moderate distal ulcerative colitis. In addition, a delayed-release capsule formulation of budesonide is indicated to reduce proteinuria in adults with IgA nephropathy at risk of rapid disease progression. In Europe, budesonide is indicated to treat eosinophilic esophagitis (EoE) in adults.
- Associated Conditions
- Allergic Reaction, Allergic Rhinitis (AR), Asthma, Bronchoconstriction, Chronic Obstructive Pulmonary Disease (COPD), Collagenous Colitis, Crohn's Disease (CD), Eosinophilic Esophagitis, Exacerbation of asthma, Nasal Congestion, Nasal Polyps, Proteinuria, Pruritus, Rhino Sinusitis, Ulcerative Colitis, Vasomotor Rhinitis, Corticosteroid-responsive dermatoses, Mild Crohn’s Disease, Moderate Crohn’s Disease
- Associated Therapies
- Maintenance therapy
Effects of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease (COPD)
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2008-08-13
- Lead Sponsor
- Queen's University
- Target Recruit Count
- 4
- Registration Number
- NCT00202189
- Locations
- 🇨🇦
Respiratory Investigation Unit, Kingston, Ontario, Canada
Effect of Nebulized Budesonide and Oral Corticosteroids on Wheezing Episode Relapse in Children
- Conditions
- Asthma
- Interventions
- Drug: Usual care (albuterol with or without oral steroid)
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2021-02-01
- Lead Sponsor
- Deborah Gentile
- Target Recruit Count
- 61
- Registration Number
- NCT00189436
- Locations
- 🇺🇸
Bellevue Pediatric Associates, Bellevue, Pennsylvania, United States
🇺🇸Allegheny General Hospital, Pittsburgh, Pennsylvania, United States
Budesonide for Maintenance Treatment of Collagenous Colitis
- Conditions
- Collagenous Colitis
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2010-03-30
- Lead Sponsor
- Technische Universität Dresden
- Target Recruit Count
- 75
- Registration Number
- NCT00180076
- Locations
- 🇩🇪
Medical Department I, Technical University Hospital, Dresden, Germany
Budesonide for Prevention of Acute Gastrointestinal GVHD Following Allogenic Stem Cell Transplantation
- Conditions
- LeukemiaGraft-Versus-Host Disease
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2010-03-30
- Lead Sponsor
- Technische Universität Dresden
- Target Recruit Count
- 242
- Registration Number
- NCT00180089
- Locations
- 🇩🇪
Medical Department I, Technical University Hospital, Dresden, Germany
Budesonide Treatment for Lymphocytic Colitis
- Conditions
- Microscopic Colitis
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2010-03-30
- Lead Sponsor
- Technische Universität Dresden
- Target Recruit Count
- 40
- Registration Number
- NCT00180050
- Locations
- 🇩🇪
Medical Department I, Technical University Hospital, Dresden, Germany
Treatment of Microscopic Colitis
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2015-01-21
- Lead Sponsor
- Norwegian University of Science and Technology
- Target Recruit Count
- 105
- Registration Number
- NCT00184171
- Locations
- 🇳🇴
Aker sykehus, Oslo, Norway
🇳🇴Helse NordMøre og Romsdal, Molde, Norway
🇳🇴Sykehuset Innlandet HF, Lillehammer, Lillehammer, Norway
A Phase IIb Trial of Pulmicort Turbuhaler (Budesonide)
- Conditions
- Lung Cancer
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2005-09-15
- Lead Sponsor
- University of British Columbia
- Target Recruit Count
- 120
- Registration Number
- NCT00175747
- Locations
- 🇨🇦
British Columbia Cancer Agency, Vancouver, British Columbia, Canada
Effect of Symbicort on GR Localisation in Asthma
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2019-09-27
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 10
- Registration Number
- NCT00159263
- Locations
- 🇬🇧
Section of Airway Disease, Asthma Lab, Imperial College London, Royal Brompton Hospital, London, United Kingdom
Long-Term Treatment of Collagenous Colitis With Budesonide
- Conditions
- Collagenous Colitis
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2008-03-06
- Lead Sponsor
- Bonderup, Ole K., M.D.
- Target Recruit Count
- 36
- Registration Number
- NCT00139165
- Locations
- 🇩🇰
Dept. of medical gastroenterology, Aarhus, Denmark
A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide
- Conditions
- Malignant Melanoma
- Interventions
- Drug: Ipilimumab+ Placebo
- First Posted Date
- 2005-08-26
- Last Posted Date
- 2016-09-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 115
- Registration Number
- NCT00135408
- Locations
- 🇬🇧
Local Institution, Hull, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.